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The 2010 Victorian influenza season was characterized by normal seasonal influenza activity and the dominance 
of the pandemic A(H1N1) 2009 strain. General Practice Sentinel Surveillance rates peaked at 9.4 ILI cases 
per 1000 consultations in week 36 for metropolitan practices, and at 10.5 ILI cases per 1000 in the following week 
for rural practices. Of the 678 ILI cases, 23% were vaccinated, a significantly higher percentage than in previous years. 
A significantly higher percentage of ILI patients were swabbed in 2010 compared to 2003–2008, but similar to 2009, 
with a similar percentage being positive for influenza as in previous years. Vaccination rates increased with patient 
age. Melbourne Medical Deputising Service rates peaked in week 35 at 19.1 ILI cases per 1000 consultations. Of the 
1914 cases of influenza notified to the Department of Health, Victoria, 1812 (95%) were influenza A infections – 
1001 (55%) pandemic A(H1N1) 2009, 4 (<1%) A(H3N2) and 807 (45%) not subtyped; 88 (5%) were influenza B; 
and 14 (<1%) were influenza A and B co-infections. The World Health Organization Collaborating Centre for Reference 
and Research on Influenza tested 403 isolates of which 261 were positive for influenza, 250 of which were influenza A 
and 11 were influenza B. Ninety-two per cent of the influenza A viruses were pandemic A(H1N1) 2009, and following 
antigenic analysis all of these were found to be similar to the current vaccine strain. Three viruses (0.9%) were found to be 
 oseltamivir resistant due to an H275Y mutation in the neuraminidase gene.
Surveillance Report
Victoria is Australia’s second most populous state with a temperate climate and an annual influenza season that usually occurs between 
May and September. Given the wide clinical spectrum 
and variable levels of diagnostic testing for influenza, 
several surveillance programmes that target different 
populations are used to monitor activity of influenza and 
influenza-like illness (ILI) in Victoria. A sentinel general 
practice (GP) programme for the surveillance of ILI in 
Victoria has been coordinated by the Victorian Infectious 
Diseases Reference Laboratory (VIDRL) in partnership 
with the Victorian Government Department of Health 
since 1993. Laboratory testing of a sample of ILI cases 
from the surveillance programme commenced in 1998.1 
VIDRL also monitors diagnoses of ILI made by the locum 
medical practitioners through the Melbourne Medical 
Deputising Service (MMDS). The Department of Health 
coordinates the surveillance of all laboratory-confirmed 
influenza in Victoria, a prescribed group B notifiable 
disease under the Victorian Public Health and Well-
being Act 2008 and Public Health and Well-being 
Regulations 2009. Th e department also investigates 
notified institutional outbreaks of respiratory illness 
under the auspices of this legislation.
The objectives of the influenza surveillance system 
are to:
• monitor the epidemiology of laboratory-confirmed 
influenza in Victoria;
• identify the onset, duration and relative severity 
of annual influenza seasons in Victoria;
• provide samples for the characterization of 
circulating influenza strains in the community to 
assist in the evaluation of the current season and 
formulation of the following season’s vaccine;
• provide potential for early recognition of new 
influenza viruses and new or emerging respiratory 
diseases; and
• estimate influenza vaccine effectiveness each 
year.
Victoria was the first Australian jurisdiction 
to report widespread transmission – particularly 
among schoolchildren – when pandemic influenza 
A(H1N1) 2009 emerged in mid-2009. While notification 
data suggested unprecedented levels of disease in the 
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community, ILI data suggested a season characterized 
as higher than normal seasonal activity.2 The pandemic 
strain continued to be dominant around the world into 
the 2009/2010 northern hemisphere influenza season 
and there was considerable interest in the epidemiology 
of a likely second southern hemisphere pandemic wave 
during the 2010 influenza season. Here we summarize 
the epidemiological findings from the Victorian influenza 
surveillance system during the 2010 season.
METHODS
General Practice Sentinel Surveillance
In 2010, 61 GPs from 23 metropolitan practices and 
26 GPs from nine rural practices participated in the 
VIDRL GP Sentinel Surveillance (GPSS) programme 
(Figure 1), which is approved for continuing professional 
development points by the Royal Australian College 
of General Practitioners and the Australian College 
of Rural and Remote Medicine for participation. 
The GPSS programme for 2010 operated from 
3 May to 24 October (weeks 19–43) inclusive.
The 87 participating GPs reported total number 
of consultations per week and age, sex and vaccination 
status of any patients presenting with ILI. GPs submitted 
the data weekly by fax or online submission (http://
www.victorianflusurveillance.com.au). A case of ILI 
was defined as fever, cough and fatigue/malaise.3 ILI 
rates were calculated as the number of ILI patients per 
1000 consultations and were compared to previously 
established activity thresholds (normal seasonal activity, 
higher than expected activity and epidemic activity) for 
Victorian influenza seasons.4
GPs were requested to collect nose and throat swabs, 
sent in the same viral transport medium, from patients 
presenting within four days or less since the onset of 
symptoms. Patients were chosen at the discretion of the 
GP. Data collected on swabbed patients included: age, 
sex, symptoms (fever, cough, fatigue, myalgia, other), 
vaccination status (for pandemic H1N1 vaccine and 
seasonal vaccine), date of vaccination/s and Aboriginal 
and/or Torres Strait Islander status. RNA was extracted 
from clinical specimens and real-time polymerase chain 
reaction (PCR) used to detect the presence of influenza 
A virus matrix gene. Influenza positive samples were 
confirmed as positive or negative for pandemic A(H1N1) 
2009 in a second real-time PCR that incorporated 
primers and probes specific for the hemagglutinin gene 
of the pandemic A(H1N1) 2009 virus. Influenza B 
viruses were identified by a separate PCR.
Melbourne Medical Deputising Service
The MMDS is the largest medical locum service in 
Australia and has contributed to Victorian influenza 
surveillance since 2003. It provides a 24-hour medical 
service to patients in their own homes or aged care 
facilities. Weekly rates of influenza-related diagnoses 
by MMDS clinicians per 1000 consultations were 
calculated from records returned from the MMDS clinical 
database using the search terms “influenza” and “flu.” 
To avoid inclusion of those immunized prophylactically, 
records that contained the terms “Fluvax,” “at risk” 
Figure 1. Distribution of sentinel surveillance practices in metropolitan and rural Victoria, 2010
RuralMetropolitan
www.wpro.who.int/wpsar12 WPSAR Vol 2, No 3, 2011 | doi: 10.5365/wpsar.2011.2.2.009
Grant et al.Flu surveillance in Victoria 2010
and “immunization” were excluded from the rate 
calculation.
Notifi cations of laboratory-confi rmed infl uenza 
to the Victorian Department of Health
Under the Victorian Public Health and Well-being Act 
2008 and Public Health and Well-being Regulations 
2009 medical practitioners and pathology services 
are required to notify laboratory-confirmed influenza 
cases to the Department of Health within five days of a 
positive test result. Records of all laboratory-confirmed 
influenza cases with a 2010 notification date were 
extracted for analysis from the Department of Health 
Notifiable Infectious Diseases Surveillance database on 
17 May 2011.
Outbreak investigations
The Victorian Department of Health investigates 
notified respiratory outbreaks in institutional settings 
under the Victorian Public Health and Well-being Act 
2008 and Public Health and Well-being Regulations 
2009. An outbreak is defined as three or more cases of 
newly acquired influenza-like illness within 72 hours in 
residents or staff of a setting or facility.
Strain typing
Seven laboratories referred specimens and isolates 
collected in Victoria during 2010 to the WHO Collaborating 
Centre for Reference and Research on Influenza, Victoria, 
Australia (WHO Collaborating Centre), although the 
selection method varied by laboratory. Tissue culture 
was attempted for all of the specimens/isolates received. 
Viruses that were successfully cultured were analysed 
by haemagglutination inhibition assay to determine 
antigenic similarity to the current vaccine strains and 
by sequencing and a neuraminidase inhibition assay to 
determine antiviral susceptibility.
Data from the surveillance systems were analysed 
descriptively using Microsoft Excel software. The 2 
test was used to compare proportions in Stata version 
10.0 statistical software, with P < 0.05 considered 
significant.
RESULTS
General Practice Sentinel Surveillance
For the 25 week surveillance period, an average 
of 93% (81/87) of GPs submitted tally sheets to 
VIDRL each week. GPs reported having conducted 
172 411 consultations (121 270 metropolitan 
and 51 141 rural) and identified 678 ILI cases 
(527 metropolitan and 151 rural) during the season, 
corresponding to metropolitan and rural rates of 4.4 and 
3.0 ILI cases per 1000 consultations, respectively.
Among the 678 ILI cases reported by GPs, the 
median age was 33 years (range: 1–91 years) and 50% 
were female. Twenty-three per cent of ILI cases were 
vaccinated in 2010. Of those vaccinated in 2010, 26% 
received the seasonal vaccine only, 38% had both the 
seasonal vaccine, which included the pandemic strain, 
and the monovalent pandemic vaccine, and 15% had 
the pandemic monovalent pandemic vaccine only. The 
remaining 20% were reported as vaccinated, but the 
vaccine was not specified.
ILI rates in 2010 were low compared to previous 
years and fell within the range of normal seasonal activity 
(Figure 2). The combined ILI rate began to increase 
in week 32 (week commencing 2 August) peaking at 
9.4 ILI cases per 1000 consultations in week 36 for 
metropolitan practices, and at 10.5 ILI cases per 1000 
in the following week for rural practices (Figure 3). Rates 
had declined to baseline levels by week 41.
GPs swabbed a total of 478 (71%) ILI patients in 
2010, of which 170 (36%) tested positive for influenza. 
In 2010, 166 (98%) of influenza positive swabs 
were influenza A and the remainder were influenza B. 
Of the 166 influenza A viruses detected, 148 (89%) 
were pandemic A(H1N1) 2009 influenza, seven (4%) 
were subtype A(H3N2) and the remaining 11 (7%) were 
not further subtyped (Table 1).
Among the influenza-positive patients, 155 (91%)
were reported as not vaccinated and 13 (8%) were 
vaccinated with the pandemic and/or seasonal vaccine(s) 
(Table 1). Higher proportions of swabbed ILI patients 
who tested negative for influenza were reported as 
vaccinated. Three patients (one influenza positive and 
two influenza negative) were reported as receiving an 
unspecified influenza vaccine and the vaccination status 
of 11 patients (two influenza positive and nine influenza 
negative) was unknown. Of the 94 patients reported 
as vaccinated, 42 (44%) had received the seasonal 
vaccine, 26 (28%) the pandemic vaccine, 23 (25%) 
both vaccines and 3 (3%) had an unspecified vaccine. 
Excluding those with unknown vaccination status, the 
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proportion of vaccinated influenza-positive patients (7%) 
was significantly lower than the proportion of vaccinated 
influenza-negative patients (27%; P < 0.001). The 
proportion of swabbed patients that were vaccinated with 
either vaccine increased with age, particularly among 
those that tested negative for influenza (Figure 4).
The median age of pandemic A(H1N1) 
2009 cases identified from the GPSS was 
26 years (range: 1–63 years), compared to 18 years 
for both influenza A(H3N2) (range: 4–34 years) and 
influenza B (range: 7–28 years), although there were 
relatively few cases of the latter two infections. Most 
Figure 2.  General Practice Sentinel Surveillance and Melbourne Medical Deputising Service influenza-like illness 
consultation rates, Victoria, 2003 to 2010
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Figure 3.  General Practice Sentinel Surveillance and Melbourne Medical Deputising Service influenza-like illness 
rates and routinely notified laboratory-confirmed influenza cases by week, Victoria, 2010
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cases (75%) identified from the GPSS were aged from 
5 to 39 years (Figure 5).
Melbourne Medical Deputising Service
A total of 441 patients were diagnosed with “flu” 
or “influenza” by the MMDS during the 2010 
surveillance season, corresponding to an overall rate of 
8.4 ILI cases per 1000 consultations. Like the 
GPSS ILI rate, the MMDS rate, with a peak of 19.1 
ILI per 1000 consultations, was low compared to 
previous seasons (Figure 2). The peak occurred in 
week 35 (week commencing 23 August) before the 
peaks of the GPSS ILI rate and cases of laboratory-
confirmed influenza notified to the Department of Health 
(Figure 3).
Notifi cations of laboratory-confi rmed infl uenza 
to the Victorian Department of Health
Excluding notifications of cases associated with 
the GPSS and outbreaks, there were 1914 cases of 
influenza routinely notified to the Department of Health 
in 2010. Of these, 1812 (95%) were influenza A 
infections, 88 (5%) were influenza B and 14 (1%) were 
influenza A and B co-infections.
Table 1. Number (%) General Practice Sentinel Surveillance swabs by influenza type/subtype, vaccination status 
and median age, Victoria, 2010
Infl uenza type/subtype Total
Vaccinated 
seasonal
(%)
Vaccinated 
pandemic 
(%)
Vaccinated
both 
(%)
Vaccinated
Unspecifi ed 
(%)
Not 
vaccinated 
(%)
Unknown 
vaccination 
status (%)
Median 
age 
(years)
All infl uenza 170 4 (2) 6 (4) 2 (1) 1 (1) 155 (91) 2 (1) 26
Pandemic A(H1N1) 2009 148 4 (3) 6 (4) 2 (1) 1 (1) 133 (90) 2 (1) 26
A(H3N2) 7 0 0 0 0 7 (100) 0 18
A (not subtyped) 11 0 0 0 0 11 (100) 0 34
B 4 0 0 0 0 4 (100) 0 18
Infl uenza negative 308 38 (12) 20 (7) 21 (7) 2 (1) 218 (71) 9 (3) 35
Total 478 42 26 23 3 373 11 32
Figure 4.  General Practice Sentinel Surveillance swabs by influenza and vaccination status and age group, 
Victoria, 2010
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The number of routinely notified cases of laboratory-
confirmed influenza, particularly influenza A, increased 
from week 31 in a pattern that was generally consistent 
with GPSS ILI rates (Figure 3). Notified cases of both 
influenza A and influenza B influenza peaked in week 37 
(week commencing 6 September), the same week as the 
GPSS rural ILI rate peak and one week after that of the 
GPSS metropolitan ILI rate.
Of the 1812 influenza A cases, 1001 (55%)   were 
pandemic A(H1N1) 2009, 4 (<1%) were A(H3N2) and 
807 (45%) were not subtyped. The median ages for 
influenza cases were 28 years (range: 0–95 years) for 
routinely notified pandemic A(H1N1), 21 years (range: 
0–94 years) for  A(H3N2) and 24 years (range: 
0–80 years) for influenza B cases. The highest proportion 
of notified cases of pandemic A(H1N1) 2009 was in the 
0–4 years age group (13%) while those aged 5–39 years 
accounted for 61% of the routinely notified cases 
(Figure 5). Overall, there was a 1:1 male-to-female ratio 
among the routinely notified cases.
Four cases aged 1 month, 27, 50 and 68 years, 
notified in weeks 34, 33, 35 and 39, respectively, were 
reported to have died as a result of influenza A virus 
infections (three due to pandemic A(H1N1) 2009 and 
the other not subtyped).
Outbreak investigations
Six respiratory outbreaks were notified to the Department 
of Health in 2010: one in week 26 (week commencing 
21 June), one in week 35 (23 August), one in week 38 
(13 September), one in week 41 (4 October) and 
two in week 44 (25 October). Four of the six outbreaks 
occurred in aged care facilities, one outbreak occurred 
in an assisted residential service, and one in a military 
facility. There were between three and 24 cases 
associated with each outbreak, corresponding to attack 
rates of 10%–45%. Of the four outbreaks in aged care 
facilities, all were caused by influenza A virus, of which 
two were influenza A (not further subtyped), one was 
due to a mixed infection [non-H1N1 and pandemic 
A(H1N1) 2009], and one was due to A(H3N2). The 
outbreaks in the assisted residential service and the 
military facility were typed as pandemic A(H1N1) 2009.
Strain typing
Of the 403 specimens and three isolates received at the 
WHO Collaborating Centre from Victoria, 261 (64%) 
yielded an influenza-positive isolate following cell culture. 
Of these, 250 (96%) were influenza A and 11 (4%) 
were influenza B. The majority (n = 231; 92%) of the 
influenza A viruses were pandemic A(H1N1) 2009, with 
17 (7%) A(H3N2); two specimens contained mixed 
Figure 5. Notified cases of laboratory confirmed influenza by age group and notification sources, Victoria, 2010
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viral populations of pandemic A(H1N1) 2009 and 
A(H3N2) viruses. Following antigenic analysis, all of the 
pandemic A(H1N1) 2009 strains were found to be similar 
to the current vaccine strain A/California/7/2009 (apart 
from two low reactors). All A(H3N2) strains were similar 
to the current vaccine strain A/Perth/16/2009 (apart from 
two low reactors) and all influenza B strains were of the 
B/Victoria/2/87 lineage and similar to the current vaccine 
strain B/Brisbane/60/2008 (apart from one low reactor). 
All (n = 261) of the Victorian influenza-positive isolates 
and 45 clinical specimens were tested for susceptibility to 
the neuraminidase inhibitors oseltamivir and zanamivir. 
Three viruses were found to be oseltamivir resistant 
due to a H275Y mutation in the neuraminidase gene. 
Two of the resistant strains came from otherwise healthy 
patients that were not under oseltamivir treatment,5 
while the third was isolated from a hospitalized child 
undergoing oseltamivir treatment.
DISCUSSION
The 2010 influenza season in Victoria was characterized 
by dominance of the pandemic A(H1N1) 2009 strain, 
which, as a seasonal second wave, was not only mild 
in magnitude as measured by ILI activity rates in 
comparison to the first wave (also in-season) in 2009 
but also compared to previous seasons back to 2003. 
Almost 90% of GPSS swabs that tested positive for 
influenza were typed as pandemic A(H1N1) 2009, 
with the remainder comprised of influenza A(H3N2), 
influenza A (not subtyped) and influenza B. This 
distribution was generally consistent among notified 
cases to the Department of Health for which typing 
data were available. Pre-pandemic H1N1 influenza 
strains were not detected in 2010, suggesting the 
pandemic A(H1N1) 2009 strain has displaced seasonal 
A(H1N1). 
Although ILI and influenza activity was lower, 
the dominance of pandemic A(H1N1) 2009 resulted 
in similarities between the 2009 and 2010 seasons, 
particularly the concentration of cases among children 
and young adults, the relatively low number of overall 
deaths and few reported ILI or influenza outbreaks in 
aged care facilities.2 Furthermore, the proportion of 
GPSS ILI cases that were swabbed was approximately 
70%, compared to 35%–50% from 2003 to 2008, 
(P < 0.001) but similar to 2009 (68%), indicating 
heightened doctor and/or patient concern with respect 
to confirmation of pandemic influenza infection. The 
proportion of GPSS swabs positive for influenza was 
36%, similar to the 39% in 20092 and the average of 
36% for the years 2003 to 2007.6
Each of the surveillance systems indicated that the 
2010 influenza season, effectively the second pandemic 
A(H1N1) 2009 influenza wave, was considerably milder 
in terms of influenza cases and ILI activity compared 
to the first season in 2009. This trend was noted in 
other southern hemisphere countries,7 but contrasts 
with the northern hemisphere and previous pandemics 
in which a mild first wave was followed by a second of 
generally greater activity and severity.8–10 The concurrent 
emergence of pandemic A(H1N1) 2009 globally 
resulted in an out-of-season first wave followed by an 
in-season second wave in the northern hemisphere. 
That the first wave in the southern hemisphere was 
in-season and followed by pandemic and seasonal 
influenza vaccination programmes may have induced 
sufficient levels of population immunity – suggested by 
serosurveys to be in the range of 16% to 26.7%11–15 – 
to help explain the difference in the relative magnitudes 
of the waves in each hemisphere. Also, 23% of ILI cases 
were vaccinated in 2010, which is significantly higher 
than the 13%–17% observed from 2005 to 2009 
(P < 0.02).
The 2010 trivalent southern hemisphere influenza 
vaccine contained the pandemic A(H1N1) 2009 strain 
(A/California/7/2009) as well as A/Perth/16/2009 
(H3N2) and B/Brisbane/60/2008. Antigenic analysis by 
the WHO Collaborating Centre indicated good matching 
with circulating strains in Victoria to those in the vaccine, 
suggesting the seasonal vaccine was effective during 
the 2010 season. This inference was supported by the 
significantly higher percentage of vaccinated influenza-
negative ILI patients compared to those that tested 
positive for influenza. Using a test-negative case control 
study design, the GPSS data were used to demonstrate 
a statistically significant protective effect of the 2010 
seasonal trivalent influenza vaccine against pandemic 
A(H1N1) 2009 infection. The vaccine effectiveness 
estimate was 79% (95% C.I.: 33%–93%) after adjusting 
for age and month of specimen collection.16
As observed in previous years, the MMDS ILI rate 
peaked slightly earlier than the corresponding GPSS 
rate, which in turn preceded the peak in notified cases 
of laboratory confirmed influenza. Thus, although less 
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specific, the ILI systems provided a more timely indication 
of influenza activity than notifiable disease data.
Given their varied source populations (e.g. those 
that seek health care from GPs and locums and the 
hospitalized young or elderly17 that make up a higher 
proportion of notified cases) the surveillance systems 
assist in providing comprehensive influenza and 
ILI surveillance in Victoria. However there are several 
limitations of the surveillance. In 2010 there was no 
systematic or timely hospital (emergency department 
and inpatient) or mortality surveillance. The Influenza 
Complications Alert Network will commence in five 
Victorian hospitals in 2011 and thus provide more 
clinical and burden of disease data associated with 
hospitalized influenza. A further limitation of the system 
is the use of different ILI case definitions by the GPSS 
and the MMDS. Although it is difficult to speculate about 
the relative sensitivity and specificity of each system, it 
is comparison of ILI rate trends over time – rather than 
absolute values between each system – that best informs 
the level of ILI activity.
Victorian influenza surveillance system reports are 
available at https://www.victorianflusurveillance.com.
au/.
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